CME Earnings

CME reported its earnings on 2026-02-04, showcasing a revenue of 1.65B against an estimate of 1.62B, resulting in a 1.77% surprise. The EPS was 2.77, surpassing the expected 2.74 by 1.09% . The stock experienced a 0.53% price change on the earnings day and a 0% change over the next five days, reflecting market reactions to the results.

Following CME's earnings announcement on 2026-02-04, the stock price moved by 0.53% on the day of the release. Over the subsequent five days, it saw a % change. Historically, CME's stock price tends to shift by an average of -2.33% in the 10 days leading up to earnings and +1.64% in the 10 days following, providing insight into potential market.

For 2026/Q1, analysts estimate CME’s annual revenue to reach 1.67B, while the EPS is projected at 2.91. These estimates reflect recent revisions, with revenue estimates revised Revenue Revise Upward by 0.43% and EPS estimates Revise Upward by 2.1% over the past three months, indicating analyst expectation in the company’s performance.

The correlation between CME's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock’s fundamentals. Over the past three months, revenue estimates for FY2025 were Revise Upward by 0.43%, while EPS estimates moved Revise Upward by 2.1% . This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, CME's stock price typically moves by -2.33% in the 10 days before its earnings and +1.64% in the 10 days after. For the upcoming 2026/Q1 earnings, analysts expect an EPS of 2.91 and revenue of 1.67B.

The earnings call summary and Q&A highlight strong financial performance, with increased revenue, operating income, and a solid cash position. The partnership with FanDuel and the new pricing strategy show proactive market engagement. Despite some unclear management responses, the overall sentiment is positive, supported by a robust market data revenue stream and strategic capital allocation. The positive guidance and effective expense management further bolster the outlook, suggesting a stock price increase of 2% to 8% over the next two weeks.